Clinical trial
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment…
NCT00105521 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00105521 |
|---|---|
| Title | Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia |
| Official title | A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia |
| Lead sponsor | EMD Serono, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson's Disease, Dyskinesia |
| Intervention type | Drug |
| Interventions | Sarizotan, Placebo |
| Enrollment | 398 |
| Start date | Sep 30, 2004 |
| Primary completion | Mar 31, 2006 |
| Completion | Mar 31, 2006 |
| First posted | Mar 16, 2005 |
| Last update posted | Apr 2, 2018 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: